baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

RAPT Therapeutics/ US75382E1091 /

10/07/2024 17:55:49	Chg. -0.06	Volume	Bid-	Ask-	High	Low
3.16USD	-1.86%	924 Turnover: 2,948.94	-Bid Size: -	-Ask Size: -	3.26	3.16

GlobeNewswire 09/05 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeut...

GlobeNewswire 09/05 RAPT Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire 09/04 RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with...

GlobeNewswire 12/03 RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT S...

GlobeNewswire 07/03 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 07/03 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 05/03 RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Associatio...

GlobeNewswire 28/02 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 21/02 RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claim...

GlobeNewswire 21/02 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...

GlobeNewswire 20/02 Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC

GlobeNewswire 20/02 RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

GlobeNewswire 13/02 RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vic...

GlobeNewswire 31/01 RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Confere...

GlobeNewswire 02/01 RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 27/11/2023 RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Tre...

GlobeNewswire 13/11/2023 RAPT Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire 03/11/2023 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free S...

GlobeNewswire 01/11/2023 RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

GlobeNewswire 18/10/2023 RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SIT...

GlobeNewswire 30/08/2023 RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

GlobeNewswire 28/03/2022 RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Mod...

GlobeNewswire 10/03/2022 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

GlobeNewswire 15/02/2022 Portage Biotech Announces New Appointments to its Management Team and Board of Directors

GlobeNewswire 09/02/2022 RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

RAPT Therapeutics/ US75382E1091 /

If you wish to receive reply to your feedback, please provide your email address.